Absci Corp (ABSI) shareholders
Close on Nov 17, 2026Market cap $1.30BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (14.40%) | 18,386,849 | 14.40% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock, Inc. | 13,396,310 | 7.80% | 13G (passive) amendment | Sep 30, 2026 |
| Sean McClain | 11,002,709 | 7.20% | 13G (passive) amendment | Sep 30, 2025 |
| Catherine D. Wood Joint filing with ARK Investment Management LLC (8.60%) | 10,955,089 | 8.60% | 13G (passive) amendment | Mar 31, 2025 |
| Phoenix General Partner II LLC Joint filing with Phoenix Venture Partners II, LP (8.20%) | 9,354,695 | 8.20% | 13G (passive) amendment | Sep 30, 2024 |
| ARK Investment Management LLC | 8,265,935 | 7.20% | 13G (passive) amendment | Dec 31, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ABSI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 25,410,048 | 14.81% | $294.50M | +2,859,051 | 0.01% |
| ARK Investment Management LLC | 12,925,271 | 7.53% | $149.80M | −800,898 | 0.97% |
| BlackRock, Inc. | 12,175,302 | 7.09% | $141.11M | +920,108 | 0.00% |
| State Street Corp | 8,097,308 | 4.72% | $93.85M | +772,450 | 0.00% |
| Ameriprise Financial Inc | 6,991,763 | 4.07% | $81.03M | +3,811,622 | 0.02% |
| Redmile Group, LLC | 6,739,675 | 3.93% | $78.11M | −1,513,641 | 5.24% |
| Vanguard Capital Management LLC | 6,122,677 | 3.57% | $70.96M | +236,037 | 0.00% |
| Advanced Micro Devices Inc | 5,714,285 | 3.33% | $66.23M | – | 5.05% |
| Adage Capital Partners Gp, L.L.C. | 5,704,820 | 3.32% | $66.12M | New | 0.09% |
| Two Sigma Investments, LP | 5,493,486 | 3.20% | $63.67M | +2,594,720 | 0.05% |
| D. E. Shaw & Co., Inc. | 5,239,754 | 3.05% | $60.73M | +4,589,937 | 0.03% |
| Geode Capital Management, LLC | 3,583,163 | 2.09% | $41.54M | +240,095 | 0.00% |
| Woodline Partners LP | 2,700,675 | 1.57% | $31.30M | −599,494 | 0.10% |
| Siren, L.L.C. | 2,474,764 | 1.44% | $28.68M | +674,764 | 0.58% |
| Bvf Inc/Il | 2,361,674 | 1.38% | $27.37M | New | 0.70% |
| Gem Investment Advisors, LLC | 2,170,863 | 1.26% | $25.16M | – | 15.43% |
| Baker Bros. Advisors LP | 2,134,803 | 1.24% | $24.74M | – | 0.12% |
| Goldman Sachs Group Inc | 1,732,324 | 1.01% | $20.08M | +1,140,612 | 0.00% |
| Nuveen, LLC | 1,723,979 | 1.00% | $19.98M | +1,381,290 | 0.00% |
| Voloridge Investment Management, LLC | 1,602,916 | 0.93% | $18.58M | New | 0.08% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 197 | 151M | 88.3% | 51 / 73 | 50 / 15 | 38M | 13M |
| Q1 2026 | 164 | 126M | 73.5% | 42 / 54 | 39 / 17 | 23M | 11M |
| Q4 2025 | 143 | 122M | 71.2% | 22 / 52 | 31 / 20 | 30M | 5M |
| Q3 2025 | 142 | 97M | 56.4% | 28 / 52 | 33 / 16 | 16M | 9M |
| Q2 2025 | 131 | 90M | 52.2% | 16 / 56 | 34 / 23 | 9M | 5M |
| Q1 2025 | 139 | 86M | 49.8% | 34 / 49 | 32 / 26 | 20M | 8M |
| Q4 2024 | 133 | 74M | 43.1% | 36 / 42 | 33 / 22 | 9M | 7M |
| Q3 2024 | 122 | 72M | 42.2% | 29 / 33 | 34 / 16 | 15M | 6M |
| Q2 2024 | 111 | 68M | 39.6% | 30 / 40 | 23 / 32 | 17M | 10M |
| Q1 2024 | 114 | 61M | 35.4% | 53 / 30 | 14 / 6 | 28M | 1M |
| Q4 2023 | 67 | 34M | 19.7% | 20 / 21 | 13 / 13 | 3M | 3M |
| Q3 2023 | 60 | 34M | 19.5% | 7 / 17 | 18 / 15 | 1M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
151 funds held ABSI in Q2 2026, 53% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ABSI | Value | % of fund | As of |
|---|---|---|---|---|---|
| ARK Genomic Revolution ETF | 10,287,893 | 5.99% | $80.04M | 5.14% | Jul 31, 2026 |
| Fidelity Growth Company Fund | 7,213,546 | 4.20% | $48.69M | 0.05% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 5,171,464 | 3.01% | $59.94M | 0.56% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,407,685 | 2.57% | $51.09M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,550,981 | 2.07% | $41.16M | 0.05% | Jun 30, 2026 |
| Columbia Acorn Fund | 2,889,066 | 1.68% | $33.48M | 1.21% | Jun 30, 2026 |
| Columbia Small Cap Growth Fund | 2,266,389 | 1.32% | $15.30M | 0.42% | May 31, 2026 |
| Fidelity Growth Company K6 Fund | 2,262,172 | 1.32% | $15.27M | 0.06% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 1,971,986 | 1.15% | $13.31M | 0.05% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 1,576,119 | 0.92% | $18.27M | 0.02% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,540,796 | 0.90% | $10.40M | 0.20% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 1,514,965 | 0.88% | $11.79M | 0.03% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 1,066,503 | 0.62% | $12.36M | 0.08% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 975,490 | 0.57% | $7.59M | 0.19% | Jul 31, 2026 |
| iShares Biotechnology ETF | 942,544 | 0.55% | $10.92M | 0.12% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sean McClain | Chief Executive Officer, Director | 10,822,389 | 6.31% | Oct 30, 2026 |
| Todd Bedrick | SVP, CAO | 199,128 | 0.12% | Oct 14, 2026 |
| Zachariah Jonasson | CFO / CBO | 484,918 | 0.28% | Oct 14, 2026 |
| Ransi Mudalinayake Somaratne | CMO, Head of R&D | – | – | Aug 7, 2026 |
| Andreas Busch | Chief Innovation Officer | 421,446 | 0.25% | Mar 16, 2026 |
| Shelby J. Walker | Chief Legal Officer | 139,775 | 0.08% | Mar 16, 2026 |
| Mary T. Szela | Director | 21,300 | 0.01% | Jul 6, 2026 |
| Karen K. McGinnis | Director | 48,420 | 0.03% | Jun 11, 2026 |
| Menelas N. Pangalos | Director | 242,408 | 0.14% | Jun 8, 2026 |
| Daniel A. Rabinovitsj | Director | 33,420 | 0.02% | Jun 8, 2026 |
| Joseph Sirosh | Director | 33,420 | 0.02% | Jun 8, 2026 |
| Houten Frans Van | Director | 73,420 | 0.04% | Jun 8, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Sean McClain Chief Executive Officer, Director | Oct 29, 2026 | Tax withholding | −79,860 | $12.10 | $966.31K | 8,552,402 |
| Sean McClain Chief Executive Officer, Director | Oct 12, 2026 | Tax withholding | −23,293 | $10.16 | $236.66K | 8,632,262 |
| Todd Bedrick SVP, CAO | Oct 12, 2026 | Tax withholding | −22,325 | $10.16 | $226.82K | 199,128 |
| Zachariah Jonasson CFO / CBO | Oct 12, 2026 | Tax withholding | −387 | $10.16 | $3.93K | 484,918 |
| Zachariah Jonasson CFO / CBO | Aug 31, 2026 | Tax withholding | −8,320 | $8.71 | $72.47K | 483,144 |
| Mary T. Szela Director | Jun 30, 2026 | Buy | +12,900 | $11.54 | $148.87K | 21,300 |
| Sean McClain Chief Executive Officer, Director | Jun 24, 2026 | Tax withholding | −59,896 | $10.08 | $603.75K | 8,655,555 |
| Mary T. Szela Director | Jun 4, 2026 | Award | +8,400 | – | – | 8,400 |
| Karen K. McGinnis Director | Jun 4, 2026 | Award | +10,100 | – | – | 48,420 |
| Mary T. Szela Director | Jun 4, 2026 | Award | +10,100 | – | – | 10,100 |
| Menelas N. Pangalos Director | Jun 4, 2026 | Award | +10,100 | – | – | 242,408 |
| Houten Frans Van Director | Jun 4, 2026 | Award | +10,100 | – | – | 73,420 |
| Daniel A. Rabinovitsj Director | Jun 4, 2026 | Award | +10,100 | – | – | 33,420 |
| Joseph Sirosh Director | Jun 4, 2026 | Award | +10,100 | – | – | 33,420 |
| Zachariah Jonasson CFO / CBO | May 31, 2026 | Tax withholding | −8,319 | $6.75 | $56.15K | 491,464 |
| Menelas N. Pangalos Director | May 13, 2026 | Buy | +37,453 | $5.36 | $200.75K | 232,308 |
| Andreas Busch Chief Innovation Officer | Mar 12, 2026 | Buy | +100,000 | $2.29 | $229.00K | 421,446 |
| Sean McClain Chief Executive Officer, Director | Mar 3, 2026 | Tax withholding | −25,316 | $2.80 | $70.88K | 8,715,451 |
| Shelby J. Walker Chief Legal Officer | Mar 3, 2026 | Tax withholding | −9,825 | $2.80 | $27.51K | 139,775 |
| Todd Bedrick SVP, CAO | Mar 3, 2026 | Tax withholding | −5,282 | $2.80 | $14.79K | 216,942 |
| Zachariah Jonasson CFO / CBO | Mar 3, 2026 | Tax withholding | −10,848 | $2.80 | $30.37K | 499,783 |
| Sean McClain Chief Executive Officer, Director | Mar 3, 2026 | Tax withholding | −25,316 | $2.80 | $70.88K | 8,715,451 |
| Todd Bedrick SVP, CAO | Mar 3, 2026 | Tax withholding | −5,282 | $2.80 | $14.79K | 216,942 |
| Shelby J. Walker Chief Legal Officer | Mar 3, 2026 | Tax withholding | −9,825 | $2.80 | $27.51K | 139,775 |
| Andreas Busch Chief Innovation Officer | Mar 3, 2026 | Tax withholding | −1,257 | $2.80 | $3.52K | 321,446 |
| Zachariah Jonasson CFO / CBO | Mar 3, 2026 | Tax withholding | −10,848 | $2.80 | $30.37K | 499,783 |
| Sean McClain Chief Executive Officer, Director | Mar 2, 2026 | Award | +406,200 | – | – | 8,740,767 |
| Shelby J. Walker Chief Legal Officer | Mar 2, 2026 | Award | +90,300 | – | – | 149,600 |
| Todd Bedrick SVP, CAO | Mar 2, 2026 | Award | +49,600 | – | – | 222,224 |
| Zachariah Jonasson CFO / CBO | Mar 2, 2026 | Award | +135,400 | – | – | 510,631 |
| Menelas N. Pangalos Director | Mar 2, 2026 | Award | +5,800 | – | – | 194,855 |
| Sean McClain Chief Executive Officer, Director | Mar 2, 2026 | Award | +406,200 | – | – | 8,740,767 |
| Todd Bedrick SVP, CAO | Mar 2, 2026 | Award | +49,600 | – | – | 222,224 |
| Shelby J. Walker Chief Legal Officer | Mar 2, 2026 | Award | +90,300 | – | – | 149,600 |
| Zachariah Jonasson CFO / CBO | Mar 2, 2026 | Award | +135,400 | – | – | 510,631 |
| Zachariah Jonasson CFO / CBO | Mar 2, 2026 | Tax withholding | −8,307 | $2.74 | $22.76K | 375,231 |
| Menelas N. Pangalos Director | Feb 27, 2026 | Buy | +75,095 | $2.74 | $205.76K | 189,055 |
| Sean McClain Chief Executive Officer, Director | Feb 23, 2026 | Tax withholding | −267,008 | $2.65 | $707.57K | 8,463,958 |
| Sean McClain Chief Executive Officer, Director | Feb 23, 2026 | Option exercise | +396,399 | $1.21 | $479.64K | 8,730,966 |
| Andreas Busch Chief Innovation Officer | Feb 3, 2026 | Tax withholding | −1,469 | $2.99 | $4.39K | 322,703 |
| Zachariah Jonasson CFO / CBO | Feb 2, 2026 | Tax withholding | −17,496 | $2.99 | $52.31K | 383,538 |
| Sean McClain Chief Executive Officer, Director | Feb 2, 2026 | Tax withholding | −26,761 | $2.99 | $80.02K | 8,334,567 |
| Zachariah Jonasson CFO / CBO | Feb 2, 2026 | Sale | −17,496 | $2.99 | $52.31K | 383,538 |
| Todd Bedrick SVP, CAO | Feb 2, 2026 | Tax withholding | −3,659 | $2.99 | $10.94K | 172,624 |
| Sean McClain Chief Executive Officer, Director | Feb 2, 2026 | Sale | −26,761 | $2.99 | $80.02K | 8,334,567 |
| Todd Bedrick SVP, CAO | Jan 28, 2026 | Award | +15,000 | – | – | 176,283 |
| Houten Frans Van Director | Dec 5, 2025 | Buy | +40,000 | $3.72 | $148.80K | 63,320 |
| Zachariah Jonasson CFO / CBO | Nov 30, 2025 | Tax withholding | −8,320 | $3.17 | $26.37K | 401,034 |
| Andreas Busch Chief Innovation Officer | Oct 14, 2025 | Tax withholding | −3,092 | $3.68 | $11.38K | 324,172 |
| Zachariah Jonasson CFO / CBO | Oct 14, 2025 | Tax withholding | −387 | $3.68 | $1.42K | 409,354 |
| Sean McClain Chief Executive Officer, Director | Oct 14, 2025 | Tax withholding | −23,293 | $3.68 | $85.72K | 8,361,328 |
| Todd Bedrick SVP, CAO | Oct 14, 2025 | Tax withholding | −21,950 | $3.68 | $80.78K | 161,283 |
| Menelas N. Pangalos Director | Sep 22, 2025 | Buy | +95,785 | $2.66 | $254.79K | 113,960 |
| Todd Bedrick SVP, CAO | Sep 22, 2025 | Buy | +10,000 | $2.70 | $27.00K | 180,428 |
| Zachariah Jonasson CFO / CBO | Aug 31, 2025 | Tax withholding | −8,319 | $2.39 | $19.88K | 409,741 |
| Andreas Busch Chief Innovation Officer | Jul 28, 2025 | Buy | +50,000 | $3.04 | $152.00K | 327,264 |
| Houten Frans Van Director | Jun 11, 2025 | Award | +14,500 | – | – | 23,320 |
| Karen K. McGinnis Director | Jun 11, 2025 | Award | +14,500 | – | – | 38,320 |
| Joseph Sirosh Director | Jun 11, 2025 | Award | +14,500 | – | – | 23,320 |
| Menelas N. Pangalos Director | Jun 11, 2025 | Award | +14,500 | – | – | 18,175 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Absci's stock actually held short. Settlement fails (shares not delivered on time) peaked at 20,300 shares on Aug 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Zachariah Jonasson Officer | Jun 13, 2024 | 19,859 | $98.89K | Jun 13, 2024 | Stock Option Exercise |
See a number that looks wrong?